FDA Grants De Novo Clearance for Reflow Medical's Spur® Peripheral Retrievable Stent System
The Spur Stent System is the first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel compliance and reduce vessel recoil effect.
Results of the recently concluded DEEPER REVEAL clinical trial (NCT05358353) to evaluate the Reflow Medical Spur Stent System for below-the-knee (BTK) treatment of chronic limb-threatening ischemia (CLTI), demonstrated that following predilatation, the Spur Stent System achieved a 99.2% technical success1 rate and 97.0% freedom from MALE2 and POD3 at 30 days.
"Clinical data submitted to the FDA demonstrated the safety and efficacy of the Spur Stent System," said Mahmood K. Razavi, MD, FSIR, FSVM, who serves as Director of the Clinical Trials and Research Center at St. Joseph Heart and Vascular Center in Orange, California. "This novel device will be a valuable and innovative expansion of our treatment toolbox as a unique device for the treatment of complex BTK disease," he added.
S. Jay Mathews, MD, MS, FACC, FSCAI, the Cath Lab Director at Bradenton Cardiology/Manatee Memorial Hospital in Bradenton, Florida, commented, "It's exciting to see the clinical success of the DEEPER REVEAL trial enabling the De Novo clearance of the Spur Stent System. This first-of-its-kind technology offers a truly novel approach to treating patients with BTK CLTI disease. As an adjunct to standard balloon angioplasty, Spur RST enables us to address this complex disease in a more effective way, achieving these outcomes that go beyond what PTA alone can deliver."
Both Dr. Mathews and Dr. Razavi were lead Principal Investigators for the study, which was conducted at 49 centers in the U.S. and enrolled 130 patients.
"Extensive research and development, which laid the groundwork for the DEEPER REVEAL trial, enabled the creation and clinical validation of the Spur Stent System, an innovative mechanical endovascular device engineered to enhance lesion penetration and optimize the treatment of BTK peripheral arterial disease," said Teo Jimenez, Senior Vice President of R&D at Reflow Medical.
According to Reflow Medical CEO and Co-Founder, Isa Rizk, "The FDA's De Novo clearance, following positive clinical trial results in patients with CLTI, enables us to provide physicians with an effective therapeutic option for this growing patient population. We are fully prepared to launch our innovative technology through our dedicated sales force, ensuring it promptly reaches physicians to support patients."
The FDA decision will be available on their website under DEN240048.
About Reflow Medical, Inc.
Reflow Medical is a global company that partners with leading physicians to develop innovative technologies addressing unmet clinical needs in the endovascular treatment of complex cardiovascular disease. The company's portfolio includes coronary and peripheral microcatheters, crossing catheters, and a revolutionary system known as Retrievable Scaffold Therapy (RST). Products include the CoraCatheters line, available in the U.S. only; the Wingman™, Spex® and Spex LP, available in the U.S., CE Mark and CE Mark-accepting countries and selected markets; and the Spur®. Spur received CE Mark approval for the treatment of restenotic lesions in below-the-knee arteries, when used in conjunction with a commercially available drug-coated balloon. Reflow Medical is headquartered in San Clemente, California.
1. Technical success defined as less than 30% residual stenosis by visual estimation; 2. Major adverse limb events; 3. Perioperative death
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529610368/en/
Contacts
Jennifer Carlylejcarlyle@reflowmedical.com 949-481-0399
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Experts reveal the hidden health side effects of lash serums
Longer, darker lashes are having a moment. For those avoiding the risk or expense of lash extensions, serums can seem like a safer, more affordable option. But not all lash serums are created equal – and some come with hidden side-effects. The key difference lies in the ingredients. Some lash serums use conditioning agents like peptides or plant oils, while others contain powerful pharmaceutical ingredients originally developed for treating eye disease. In 2001, a new medication called bimatoprost was approved to treat glaucoma and ocular hypertension – two conditions involving pressure buildup inside the eye that can damage the optic nerve and cause vision loss. Unlike earlier treatments, bimatoprost worked well for patients who hadn't responded to other drugs, had fewer systemic side effects (effects on the whole body rather than just the eye) and required less frequent dosing than some other glaucoma drops. But doctors soon noticed something unexpected: their patients' eyelashes were growing longer, thicker and darker. Researchers still don't fully understand how bimatoprost stimulates lash growth, but it appears to extend the anagen phase – the active growth phase – of the lash life cycle. In 2008, the same drug (now marketed as Latisse) was approved by the US Food and Drug Administration (FDA), the federal agency responsible for evaluating the safety and effectiveness of drugs and medical devices, to treat eyelash hypotrichosis, a condition where eyelashes are sparse or missing. It was initially prescribed for people who had lost their lashes due to chemotherapy, alopecia areata (an autoimmune disorder causing hair loss), or trichotillomania (a compulsive hair-pulling condition). Extensive research shows that bimatoprost is effective at making lashes longer, thicker and darker, with noticeable results after 16 weeks of daily use. But the results are temporary: once you stop using it, your lashes return to their natural growth cycle. Side-effects Bimatoprost belongs to a class of medications called prostaglandin analogues (PGAs), which have been widely used in eye care since the 1990s. Because of this, its side effects are well documented. When used for lash growth, bimatoprost can cause burning, redness, dryness and eye irritation. These usually go away when the product is stopped. But there are also more serious cosmetic changes to be aware of, including darkening of the skin on the eyelid, fat loss around the eyes, creating a hollow, sunken look, permanent iris darkening (the coloured part of the eye), unwanted hair growth where the serum spreads and, in rare cases, drooping of the upper eyelid, which may require surgery to correct. In the UK, bimatoprost remains a prescription-only medication. However, the boom in over-the-counter lash serums sold online and in shops has made similar products more accessible – and potentially more confusing. A recent investigation by the UK government found that almost one in four lash serums sold in the UK contain PGAs such as isopropyl cloprostenate. This chemical is not as well studied as bimatoprost, but case reports suggest it can cause skin darkening, dryness and hollowing of the eye area, sometimes after just a few weeks of use. In the US, the FDA issued warnings over a decade ago stating that any cosmetic product containing these ingredients and making growth claims should be treated as a drug, not a cosmetic. Consumers may be unaware they're using a pharmaceutical-mimicking ingredient. Sweden banned PGAs in lash serums in 2013. Canada prohibits them in all cosmetic products. Even if a product claims to be 'PGA-free,' check the ingredients list: anything ending in '-prost' is a red flag. 'Natural' or peptide-based alternatives Some lash serums use peptides, which may help strengthen lashes by boosting keratin or supporting follicle health. These are often combined with conditioning agents to reduce breakage. While seen as a gentler alternative to PGAs, most studies on peptides focus on scalp hair, not eyelashes, so evidence for lash growth is limited. Other serums rely on castor oil or plant-based extracts, but their effectiveness is largely anecdotal and not supported by robust science. There is no guaranteed, side-effect-free way to make lashes grow dramatically longer. Prescription lash serums like bimatoprost are proven to work – but they come with potential risks, especially with long-term use. Over-the-counter products may seem safer, but many contain hidden prostaglandin analogues buried deep in the ingredients list with similar side effects. Peptide and oil-based serums are less risky, but there's little strong evidence that they work. Our eyes are delicate and, unlike beauty trends, they're not replaceable. If you're thinking about enhancing your lashes, read the label, do your research and speak to an eye care professional. The price of longer lashes shouldn't be your eye health. Alison Ng is a Lecturer in Optometry and Vision Sciences at Cardiff University Byki Huntjens is an Honorary Senior Research Fellow in Optometry in the School of Health & Medical Sciences, City St George's at the University of London. This article is republished from The Conversation under a Creative Commons license. Read the original article.
USA Today
an hour ago
- USA Today
The natural alternative to food dyes you may not know about
As Americans re-evaluate their relationship with synthetic food dyes, blue spirulina has emerged as a popular natural alternative. It has been used in food internationally for centuries, adopted by NASA as a supplement for astronauts in space and more recently has evolved to land in health food stores and pricy, celebrity-backed smoothies in Los Angeles. Researchers have found some health benefits, but nutrition experts warn against getting carried away with thinking that blue spirulina is something you should necessarily be consuming in large quantities. "There are some benefits, but the hype is largely due to its Instagram-worthy color," says Washington, D.C.-based dietitian Caroline Thomason. Noted Bella Hadid, Erehwon, TikTok influencers are using sea moss. Is it actually good for you? What is blue spirulina? Blue spirulina is a bright blue extract of green spirulina (a type of blue-green algae), which is classified as a type of cyanobacteria, per Harvard Health. "It gets its vibrant hue from phycocyanin, a powerful antioxidant that you can't find in any other land plants," Thomason says. The U.S. Food and Drug Administration (FDA) originally approved blue spirulina in 2013 as a natural alternative to blue food dyes in candy and gum, and more recently expanded its approval for a slew of other food and drink products including non-alcoholic beverages, condiments, dairy alternatives, salad dressings, seasoning mixes and alcoholic beverages with under 20% alcoholic content. Any type of color additive must be approved by the FDA prior to the product hitting the market, and that product may only be used for the specific uses and perameters dictated by the FDA, per the agency. When the FDA approves a product, the organization has determined that the benefits outweigh the downsides, but that doesn't mean there aren't any. The FDA classifies blue spirulina as a color additive that's exempt from certification, which means individual batches of food that contain the extract don't need to be certified before hitting shelves. Harvard Health notes that means "there's no guarantee that the product you buy will be contaminant-free or contain the amount of spirulina promised on the label." Between 2018 and 2020, three blue-green algae products (two supplements and a beverage) were recalled after being found to have higher levels of microcystins, a natural toxin that can cause liver and kidney damage, than permitted by the Environmental Protection Agency (EPA) and the World Health Organization (WHO). "It's generally safe in small amounts, though the quality can vary between brands," Thomason says. "It's important to choose a reputable source to avoid contamination with heavy metals or toxins, which can happen in poorly regulated algae products." In case you missed: What is ashwagandha and what does it do for the body? What is blue spirulina good for? Other types of spirulina are usually higher in nutrients. "While it doesn't contain the full nutritional profile of whole spirulina, it still offers antioxidants that may help lower inflammation, the same kind you'd find in colorful fruits and vegetables like blueberries or red cabbage," Thomason says. "Adding blue spirulina to your routine isn't a bad thing at all, and it can be part of a fun and diverse diet. But as with any superfood, going overboard might create nutrient gaps or generally just an unhealthy fixation."
Medscape
3 hours ago
- Medscape
Philips Respironics Updates Device Use Correction
Philips Respironics has updated use instructions for three bi-level positive airway pressure machines, according to a recall statement posted by the US FDA. The recall does not include removal of the devices from the market; instead, it provides instructions for correcting the devices in the event of interruptions in or loss of therapy. The updated use instructions apply to the Philips Respironics' BiPAP A30, BiPAP A40, and BiPAP V30 Auto, all lots, according to the statement. The company is issuing updated instructions because of the risk for potential failure in the ventilator inoperative alarm. This failure can cause interruption or loss of therapy and has been associated with 13 injuries and 8 deaths. The devices are designed to provide noninvasive breathing support for adults and children who weigh more than 22 pounds with obstructive sleep apnea and respiratory insufficiency. According to the statement, any of the affected devices may reboot intermittently, meaning a 5-10 second period of no therapy, with a blank screen and a single audible alert. The devices may then restart with the same patient settings, or they may reboot intermittently and restart with their factory default settings. Additionally, the devices have been reported to enter a 'ventilator inoperative' state during which therapy stops and audible and visual alarms are present. 'These issues can result in therapy interruption or loss, potentially leading to hypoventilation, hypoxemia, hypercarbia, respiratory failure, or death in vulnerable patients,' according to the statement. The BiPAP A30 and BiPAP A40 are suitable for home use and clinical use; the BiPAP V30 Auto is for use in hospitals or institutions. If the ventilator inoperative alarm occurs, patients who can tolerate interruptions of therapy should be placed on an alternative device; patients who can't tolerate a therapy interruption should be given alternate ventilation, and clinicians should contact their equipment supplier for an immediate device alternative, according to the recall. A hard reboot may temporarily restore the device, according to the statement. Healthcare professionals and consumers may report adverse reactions or quality problems associated with these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
